abstract |
The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from 0, N, NR1, and S(O)¿p?, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP) , TNF-a converting enzyme (TACE) , aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same. |